Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCT05193578 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a home-based program using semaglutide can help lower blood sugar levels in adults with schizophrenia who have prediabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 154 people

Who can join Ages 18–60 · all sexes

Timeline Started 2022-01 · est. completion 2024-05

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT05193578 ↗

Description as written by the study sponsor.

To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic treatment. Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic symptoms and quality of life in people with schizophrenia, prediabetes and overweight.

Treatments tested

Semaglutide, 1.34 mg/mL Drug

Semaglutide, 1.34 mg/mL
Placebo Other

Semaglutide-Placebo

Main thing measured	HbA1c (mmol/mol)
Sponsor	Jan Frystyk
Conditions studied	Schizophrenia, Prediabetic State
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05193578 ↗